Aclaris Therapeutics
Stage
IPO | IPOTotal Raised
$82MDate of IPO
10/7/2015Market Cap
0.81BStock Price
12.25About Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical dermatology company focused on the development of dermatologic therapies. The company focuses on identifying, developing, and commercializing topical dermatological technologies that fill unmet medical needs. The lead product in the Aclaris product portfolio (A-101) is currently a pre-IND asset that is being developed as a topical treatment for both medical and aesthetic indications.
Aclaris Therapeutics Headquarter Location
640 Lee Rd Suite 200
Wayne, Pennsylvania, 19087,
United States
484-321-5554
Research containing Aclaris Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aclaris Therapeutics in 1 CB Insights research brief, most recently on Oct 29, 2021.
Expert Collections containing Aclaris Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aclaris Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Aclaris Therapeutics Patents
Aclaris Therapeutics has filed 23 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Dermal and subcutaneous growths
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/12/2019 | 6/1/2021 | Racing car classes, Sports car racing, Inflammations, Rally cars, Touring car racing | Grant |
Application Date | 8/12/2019 |
|---|---|
Grant Date | 6/1/2021 |
Title | |
Related Topics | Racing car classes, Sports car racing, Inflammations, Rally cars, Touring car racing |
Status | Grant |
Latest Aclaris Therapeutics News
May 9, 2022
May 09, 2022 1:49 PM ETBy: Dania Nadeem , SA News Editor Aclaris Therapeutics ( ACRS ) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $1.67M (-6.2% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 2 downward. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Aclaris Therapeutics Web Traffic
Aclaris Therapeutics Rank
Where is Aclaris Therapeutics's headquarters?
Aclaris Therapeutics's headquarters is located at 640 Lee Rd, Wayne.
What is Aclaris Therapeutics's latest funding round?
Aclaris Therapeutics's latest funding round is IPO.
How much did Aclaris Therapeutics raise?
Aclaris Therapeutics raised a total of $82M.
Who are the investors of Aclaris Therapeutics?
Investors of Aclaris Therapeutics include Kenexa.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.